HR negative

This study underscores that the management of suspected malignant transformation of adenomyosis requires multidisciplinary evaluation. More importantly, our findings demonstrate that aggressive treatment should be initiated even without definitive pathological confirmation when clinical suspicion is high. The significance of this work lies in its contribution to recognizing the heterogeneous nature of EC-AIA, urging future research to focus on elucidating molecular mechanisms and developing personalized therapeutic strategies for these aggressive variants.

HER2 expression levels (low/ultralow/null) stratify prognosis in HER2-negative eBC. The dynamic evolution of HER2 status following NAC and its prognostic utility highlights the importance of reassessing HER2 status in residual disease in HER2-negative eBC.

We report a 60-year-old woman with HER2-positive, hormone receptor-negative breast cancer who achieved pCR after neoadjuvant docetaxel combined with trastuzumab and pertuzumab, followed by 12 months of maintenance trastuzumab and pertuzumab. Emerging CNS-active therapies, including small-molecule tyrosine kinase inhibitors (TKIs) such as tucatinib and next-generation antibody-drug conjugates (ADCs) like trastuzumab deruxtecan, have shown promising intracranial activity. In addition, advanced strategies such as intensified MRI surveillance, radiomics, liquid biopsy, focused ultrasound-mediated BBB disruption, nanoparticle delivery systems, and radionuclide therapy offer potential avenues for early identification and prevention of cerebral metastases.

Adjuvant chemotherapy may optimize survival in select patients with T1b-T2N0M0 MBC, though prospective validation is warranted.

Ki67 appears to be an important prognostic biomarker in HR+ breast cancer across both HER2-low and HER2-positive subgroups. Dual stratification by HER2 and Ki67 status may improve risk assessment and help identify high-risk subgroups who could benefit from treatment approaches beyond endocrine therapy alone. These findings warrant confirmation in prospective studies.

P2, N=36, Recruiting, Laura Huppert, MD, BA | Not yet recruiting --> Recruiting

And small-tumor breast cancer patients do not usually benefit from AC. AC may not be recommended for certain subgroups, such as patients with pT1mi/a-bN0-1 HR+HER2- or pT1mi/a-bN0 HR-HER2-/HR+HER2+ can be exempted from chemotherapy.

The patient underwent a modified radical mastectomy followed by adjuvant chemotherapy and trastuzumab...This case highlights the diagnostic challenge of PCD, particularly when neurological manifestations precede tumor detection, and suggests that HER2-positive breast cancer may also be associated with anti-Yo antibodies. Early recognition of this syndrome and systematic malignancy screening are essential to improve patient outcomes.

P3, N=474, Completed, Istituto Oncologico Veneto IRCCS | Active, not recruiting --> Completed

Whole-genome sequencing of tumor samples carrying these germline risk variants revealed that they harbored mutational signatures indicative of a deficiency of homologous recombination. These findings suggest that hereditary POLH p.K589T and RAD51 p.M1fs are candidate variants associated with an increased risk of hormone receptor-negative breast cancer.

With adequate follow-up, distant disease-free survival is a robust surrogate endpoint for predicting final overall survival outcomes in neoadjuvant RCTs for early breast cancer in most contexts. However, the distant disease-free survival surrogacy appears to be weak for the hormone receptor-positive and HER2-negative and for the hormone receptor-positive and HER2-positive molecular subtypes. These latter findings warrant further investigation in more recent RCTs enrolling higher-risk patient populations.

Exploratory subgroup analysis further elucidated that OW/OB patients, particularly those aged > 50 years, postmenopausal, with lymph node involvement, hormone receptor negativity, or HER2 3 + status, exhibited substantially compromised pCR rates. Collectively, these findings substantiate the potential of BMI as a robust predictive biomarker for neoadjuvant therapy response in Chinese HER2-positive breast cancer patients.